Daniel Passeri - Sep 30, 2021 Form 4 Insider Report for Cue Biopharma, Inc. (CUE)

Role: CHIEF EXECUTIVE OFFICER, Director
Signature: /s/ Daniel Passeri by Colin Sandercock, attorney-in-fact
Stock symbol: CUE
Transactions as of: Sep 30, 2021
Transactions value $: -$461,534
Form type: 4
Date filed: 10/8/2021, 04:00 PM
Previous filing: Sep 27, 2021
Next filing: Mar 29, 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CUE	Common Stock	Options Exercise		+75K	+135.44%		130K	Sep 30, 2021	Direct	F1
transaction	CUE	Common Stock	Tax liability	-$462K	-31.7K	-24.3%	$14.57^*	98.7K	Sep 30, 2021	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CUE	Restricted Stock Units	Options Exercise	$0	-75K	-50%	$0.00	75K	Sep 30, 2021	Common Stock	75K		Direct	F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents shares of common stock received upon vesting of a restricted stock unit award.
F2	Each restricted stock unit award represents a contingent right to receive one share of common stock.
F3	One half of the Restricted Stock Units vested on September 30, 2021 and the balance will vest on March 31, 2022.